Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Esophageal Neoplasms 11Pancreatic Neoplasms 7Cholangiocarcinoma 6Liver Neoplasms 5Colonic Neoplasms 4Neoplasms 3Colorectal Cancer Metastatic 3Spinocerebellar Degenerations 2Neoplasm Metastasis 2Locally Advanced Rectal Cancer 2Liver Diseases 2Gastric Adenocarcinoma 2Advanced Biliary Tract Cancer 2Uterine Cervical Neoplasms 1Unresectable Locally Advanced Pancreatic Cancer 1Turcot syndrome 1Tislelizumab 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1PD-1 Antibody 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Microsatellite Stable Metastatic Colorectal Cancer 1

Interventions

Leucovorin 2Fluorouracil 2Cetuximab 2Bevacizumab 2spartalizumab 1sintilimab 1Radiotherapy 1Radiation Dose Hypofractionation 1Oxaliplatin 1Irinotecan 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Recurrent Rectal Cancer × sintilimab × Gastrointestinal × Clear all
NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Fudan University

Phase 2 Recruiting
221 enrolled
Gastrointestinal

Locally Recurrent Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡